High-affinity monoclonal antibody pair development for lateral flow assays

Overview

This service delivers custom high-affinity, low off-rate monoclonal antibody pairs specifically developed and validated for lateral flow and sandwich assay applications. Using proprietary immunization and hybridoma technologies, the platform produces antibody pairs with binding affinities in the picomolar to femtomolar range and off-rates below 5 x 10⁻⁴ 1/s. The approach emphasizes selecting antibodies that recognize target analytes in solution, which is critical for accurate lateral flow performance. With a reported delivery success rate exceeding 95%, compared to an industry average below 50%, this offering targets diagnostic developers, biopharmaceutical companies, and research institutions needing reliable antibody reagents for assay development.

Technical specifications

Key capabilities and features:

• Proprietary immunization protocol generates hyper-immune IgG titers against the target immunogen in approximately three weeks
• Advanced hybridoma generation producing more than ten times the number of hybridoma cells compared to traditional polyethylene glycol fusion methods
• Direct cloning of hybridoma cells without limited dilution assays, accelerating clone isolation
• Real-time binding kinetic analyses to identify clones producing high-affinity, low off-rate monoclonal antibodies
• In-solution epitope binning assays to identify antibody pairs compatible with lateral flow formats
• Affinity-matured antibodies with dissociation constants ranging from nanomolar to femtomolar
• Optional enzyme conjugation of produced antibodies for ready-to-use assay integration
• Application-specific immunogen and screening antigen design to ensure antibodies function in the client's intended assay format
• AAALAC- and OLAW-accredited laboratory facilities supporting research and production workflows

Technology readiness level

The antibody development platform is fully commercial and has been validated through more than 23 years of continuous service delivery, with antibody pairs routinely delivered in approximately 60 days or less. The technology has been applied for global biopharmaceutical companies, diagnostic firms, and federal research institutions including NIAID and NCI, with many clients engaging as repeat customers. Antibodies developed through this platform are accessible through the NCI Clinical Proteomic Technologies for Cancer (CPTC) antibody portal. The standard engagement workflow includes initial confidential discussion, statement of work development, phase-based results sharing, clone selection, small-scale production and purification, and delivery of antibodies with an optional comprehensive report.